Sublingual microcirculatory effects of enalaprilat in an ovine model of septic shock

Shock

Volumn 35, Issue 6, 2011, Pages 542-549

  Salgado, Diamantino Ribeiro ^a,b   He, Xinrong ^a   Su, Fuhong ^a   De Sousa, Dalton Barros ^a   Penaccini, Laura ^a   MacIel, Leonardo Kfuri ^a   Taccone, Fabio ^a   Rocco, José Rodolfo ^b   Silva, Eliézer ^c,d   De Backer, Daniel ^a   Vincent, Jean Louis ^a  

^a ERASME HOSPITAL   (Belgium)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^d HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

Author keywords

Angiotensin II; renal function; sublingual microcirculation

Indexed keywords

ANGIOTENSIN II; CREATININE; ENALAPRILAT; NORADRENALIN; OXYGEN; PLACEBO; SODIUM CHLORIDE;

ANGIOTENSIN BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ARTIFICIAL VENTILATION; BLOOD FLOW; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FECES; FEMALE; FLUID RESUSCITATION; GAS EXCHANGE; HEMODYNAMIC PARAMETERS; HYPOTENSION; KIDNEY FUNCTION; LUNG FUNCTION; MEAN ARTERIAL PRESSURE; MICROCIRCULATION; MICROSCOPY; NONHUMAN; OXYGEN TENSION; PERFUSION; PERITONEAL CAVITY; RANDOMIZED CONTROLLED TRIAL; SEPTIC SHOCK; SHEEP; SINGLE DRUG DOSE; SURVIVAL TIME;

ANGIOTENSIN II; ANIMALS; ENALAPRILAT; FEMALE; FLUID THERAPY; MICROCIRCULATION; MOUTH FLOOR; PLACEBOS; RANDOM ALLOCATION; SHEEP, DOMESTIC; SHOCK, SEPTIC;

EID: 79957913825     PISSN: 10732322     EISSN: 15400514     Source Type: Journal    
DOI: 10.1097/SHK.0b013e3182115e6a     Document Type: Article

References (47)

1. Angus DC, Wax RS: Epidemiology of sepsis: an update. Crit Care Med 29: S109-S116, 2001. (Pubitemid 32681592)
2. Martin GS, Mannino DM, Eaton S, Moss M: The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 348:1546-1554, 2003. (Pubitemid 36437931)
3. Bone RC, Grodzin CJ, Balk RA: Sepsis: a new hypothesis for pathogenesis of the disease process. Chest 112:235-243, 1997. (Pubitemid 27343624)
4. De Backer D, Creteur J, Preiser JC, Dubois MJ, Vincent JL: Microvascular blood flow is altered in patients with sepsis. Am J Respir Crit Care Med 166: 98-104, 2002. (Pubitemid 34693970)
5. Sakr Y, Dubois MJ, De Backer D, Creteur J, Vincent JL: Persistent micro-circulatory alterations are associated with organ failure and death in patients with septic shock. Crit Care Med 32:1825-1831, 2004. (Pubitemid 39202356)
6. Trzeciak S, McCoy JV, Phillip DR, Arnold RC, Rizzuto M, Abate NL, Shapiro NI, Parrillo JE, Hollenberg SM: Early increases in microcirculatory perfusion during protocol-directed resuscitation are associated with reduced multi-organ failure at 24 h in patients with sepsis. Intensive Care Med 34:2210-2217, 2008.
7. Goedhart PT, Khalilzada M, Bezemer R, Merza J, Ince C: Sidestream dark field (SDF) imaging: a novel stroboscopic LED ringYbased imaging modality for clinical assessment of the microcirculation. Opt Express 15:15101-15114, 2007. (Pubitemid 350127674)
8. Rolih CA, Ober KP: The endocrine response to critical illness. Med Clin North Am 79:211-224, 1995.
9. du Cheyron D, Lesage A, Daubin C, Ramakers M, Charbonneau P: Hyper-reninemic hypoaldosteronism: a possible etiological factor of septic shock-induced acute renal failure. Intensive Care Med 29:1703-1709, 2003. (Pubitemid 37373813)
10. Hilgenfeldt U, Kienapfel G, Kellermann W, Schott R, Schmidt M: Renin-angiotensin system in sepsis. Clin Exp Hypertens A 9:1493-1504, 1987. (Pubitemid 17128303)
11. Cumming AD, Driedger AA, McDonald JW, Lindsay RM, Solez K, Linton AL: Vasoactive hormones in the renal response to systemic sepsis. Am J Kidney Dis 11:23-32, 1988. (Pubitemid 18041902)
12. Tamion F, Cam-Duchez V, Menard JF, Girault C, Coquerel A, Bonmarchand G: Erythropoietin and renin as biological markers in critically ill patients. Crit Care 8:R328-R335, 2004.
13. Duprez DA: Role of the renin-angiotensin-aldosterone system in vascular remodeling and inflammation: a clinical review. J Hypertens 24:983-991, 2006. (Pubitemid 43772300)
14. Miyoshi M, Nagata K, Imoto T, Goto O, Ishida A, Watanabe T: Ang II is involved in the LPS-induced production of proinflammatory cytokines in dehydrated rats. Am J Physiol Regul Integr Comp Physiol 284:R1092-R1097, 2003. (Pubitemid 36406870)
15. Suzuki Y, Ruiz-Ortega M, Lorenzo O, Ruperez M, Esteban V, Egido J: Inflammation and angiotensin II. Int J Biochem Cell Biol 35:881-900, 2003. (Pubitemid 36379329)
16. Duprez DA: Angiotensin II, platelets and oxidative stress. J Hypertens 22: 1085-1086, 2004. (Pubitemid 38720996)
17. Imai Y, Kuba K, Rao S, Huan Y, Guo F, Guan B, Yang P, Sarao R, Wada T, Leong-Poi H, et al.: Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature 436:112-116, 2005. (Pubitemid 40966195)
18. Lund DD, Brooks RM, Faraci FM, Heistad DD: Role of angiotensin II in endothelial dysfunction induced by lipopolysaccharide in mice. Am J Physiol Heart Circ Physiol 293:H3726-H3731, 2007. (Pubitemid 350230920)
19. Saavedra JM, Benicky J, Zhou J: Mechanisms of the anti-ischemic effect of angiotensin II AT(1) receptor antagonists in the brain. Cell Mol Neurobiol 26: 1099-1111, 2006. (Pubitemid 44924033)
20. Yasuda S, Lew WY: Angiotensin II exacerbates lipopolysaccharide-induced contractile depression in rabbit cardiac myocytes. Am J Physiol 276:H1442-H1449, 1999. (Pubitemid 29246529)
21. Hagiwara S, Iwasaka H, Hidaka S, Hasegawa A, Koga H, Noguchi T: Antagonist of the type-1 ang II receptor prevents against LPS-induced septic shock in rats. Intensive Care Med 35:1471-1478, 2009.
22. Hagiwara S, Iwasaka H, Matumoto S, Hidaka S, Noguchi T: Effects of an angiotensin-converting enzyme inhibitor on the inflammatory response in in vivo and in vitro models. Crit Care Med 37:626-633, 2009.
23. Freise H, Palmes D, Spiegel HU: Inhibition of angiotensin-converting enzyme reduces rat liver reperfusion injury via bradykinin-2-receptor. J Surg Res 134: 231-237, 2006. (Pubitemid 44092797)
24. Riaz AA, Wang Y, Schramm R, Sato T, Menger MD, Jeppsson B, Thorlacius H: Role of angiotensin II in ischemia/reperfusion-induced leukocyte-endothelium interactions in the colon. FASEB J 18:881-883, 2004.
25. Laesser M, Oi Y, Ewert S, Fandriks L, Aneman A: The angiotensin II receptor blocker candesartan improves survival and mesenteric perfusion in an acute porcine endotoxin model. Acta Anaesthesiol Scand 48:198-204, 2004. (Pubitemid 38166465)
26. Nitescu N, Grimberg E, Guron G: Low-dose candesartan improves renal blood flow and kidney oxygen tension in rats with endotoxin-induced acute kidney dysfunction. Shock 30:166-172, 2008.
27. Boldt J, Papsdorf M, Kumle B, Piper S, Hempelmann G: Influence of angio-tensin-converting enzyme inhibitor enalaprilat on endothelial-derived substances in the critically ill. Crit Care Med 26:1663-1670, 1998. (Pubitemid 28467674)
28. Schmidt H, Hoyer D, Rauchhaus M, Prondzinsky R, Hennen R, Schlitt A, Carter J, Hottenrott K, Muller-Werdan U, Werdan K, et al.: ACE-inhibitor therapy and survival among patients with multiorgan dysfunction syndrome (MODS) of cardiac and non-cardiac origin. Int J Cardiol 140:296-303, 2010.
29. De Backer D, Hollenberg S, Boerma C, Goedhart P, Buchele G, Ospina-Tascon G, Dobbe I, Ince C: How to evaluate the microcirculation: report of a round table conference. Crit Care 11:R101, 2007.
30. Trzeciak S, Dellinger RP, Parrillo JE, Guglielmi M, Bajaj J, Abate NL, Arnold RC, Colilla S, Zanotti S, Hollenberg SM: Early microcirculatory perfusion derangements in patients with severe sepsis and septic shock: relationship to hemo-dynamics, oxygen transport, and survival. Ann Emerg Med 49(98):88-98, 2007.
31. Wiel E, Pu Q, Leclerc J, Corseaux D, Bordet R, Lund N, Jude B, Vallet B: Effects of the angiotensin-converting enzyme inhibitor perindopril on endo-thelial injury and hemostasis in rabbit endotoxic shock. Intensive Care Med 30:1652-1659, 2004. (Pubitemid 39094969)
32. Spronk PE, Ince C, Gardien MJ, Mathura KR, Oudemans-van Straaten HM, Zandstra DF: Nitroglycerin in septic shock after intravascular volume resuscitation. Lancet 360:1395-1396, 2002. (Pubitemid 35341307)
33. Boerma EC, Koopmans M, Konijn A, Kaiferova K, Bakker AJ, van Roon EN, Buter H, Bruins N, Egbers PH, Gerritsen RT, et al.: Effects of nitroglycerin on sublingual microcirculatory blood flow in patients with severe sepsis/septic shock after a strict resuscitation protocol: a double-blind randomized placebo controlled trial. Crit Care Med 38:93-100, 2010.
34. De Backer D, Creteur J, Dubois MJ, Sakr Y, Koch M, Verdant C, Vincent JL: The effects of dobutamine on microcirculatory alterations in patients with septic shock are independent of its systemic effects. Crit Care Med 34:403-408, 2006. (Pubitemid 43145619)
35. Arnold RC, Parrillo JE, Phillip DR, Chansky ME, Shapiro NI, Lundy DJ, Trzeciak S, Hollenberg SM: Point-of-care assessment of microvascular blood flow in critically ill patients. Intensive Care Med 35:1761-1766, 2009.
36. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, Reinhart K, Angus DC, Brun-Buisson C, Beale R, et al.: Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 36:296-327, 2008.
37. Trzeciak S, Cinel I, Phillip DR, Shapiro NI, Arnold RC, Parrillo JE, Hollenberg SM: Resuscitating the microcirculation in sepsis: the central role of nitric oxide, emerging concepts for novel therapies, and challenges for clinical trials. Acad Emerg Med 15:399-413, 2008.
38. Wan L, Langenberg C, Bellomo R, May CN: Angiotensin II in experimental hyperdynamic sepsis. Crit Care 13:R190, 2009.
39. Su F, Brands R, Wang Z, Verdant C, Bruhn A, Cai Y, Raaben W, Wulferink M, Vincent JL: Beneficial effects of alkaline phosphatase in septic shock. Crit Care Med 34:2182-2187, 2006. (Pubitemid 44305623)
40. Su F, Wang Z, Cai Y, Rogiers P, Vincent JL: Fluid resuscitation in severe sepsis and septic shock: albumin, hydroxyethyl starch, gelatin or ringer's lactate-does it really make a difference? Shock 27:520-526, 2007. (Pubitemid 46626079)
41. Laesser M, Fandriks L, Pettersson A, Ewert S, Aneman A: Angiotensin II blockade in existing hypovolemia: effects of candesartan in the porcine splanchnic and renal circulation. Shock 14:471-477, 2000.
42. Boldt J, Menges T, Wollbruck M, Harter K, Hempelmann G: Continuous i.v. administration of the angiotensin-converting enzyme inhibitor enalaprilat in the critically ill: effects on regulators of circulatory homeostasis. J Cardiovasc Pharmacol 25:416-423, 1995.
43. van de Wal RM, Plokker HW, Lok DJ, Boomsma F, van der Horst FA, van Veldhuisen DJ, van Gilst WH, Voors AA: Determinants of increased angio-tensin II levels in severe chronic heart failure patients despite ACE inhibition. Int J Cardiol 106:367-372, 2006. (Pubitemid 41766640)
44. Geary KM, Hunt MK, Peach MJ, Gomez RA, Carey RM: Effects of angiotensin converting enzyme inhibition, sodium depletion, calcium, isoproterenol, and angiotensin II on renin secretion by individual renocortical cells. Endocrinology 131:1588-1594, 1992.
45. Shariat-Madar Z, Schmaier AH: The plasma kallikrein/kinin and renin angio-tensin systems in blood pressure regulation in sepsis. J Endotoxin Res 10:3-13, 2004. (Pubitemid 38461247)
46. Warren JB, Loi RK: Captopril increases skin microvascular blood flow secondary to bradykinin, nitric oxide, and prostaglandins. FASEB J 9:411-418, 1995.
47. Mustafa SS, Rivers RJ, Frame MD: Microcirculatory basis for nonuniform flow delivery with intravenous nitroprusside. Anesthesiology 91:723-731, 1999. (Pubitemid 29418654)